Steven Cohen's KROS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 109,015 shares of Keros Therapeutics, Inc. (KROS) worth $1.2 M, representing 0.00% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in KROS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 890,651 shares. Largest reduction occurred in Q4 2024, reducing 945,978 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Keros Therapeutics (KROS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Keros Therapeutics (KROS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +70,167 | Add 180.62% | 109,015 | $11.04 |
| Q4 2025 | +38,848 | New Buy | 38,848 | $20.36 |
| Q2 2025 | -6 | Sold Out | 0 | $0.00 |
| Q1 2025 | -1,586 | Reduce 99.62% | 6 | $9.83 |
| Q4 2024 | -945,978 | Reduce 99.83% | 1,592 | $15.83 |
| Q3 2024 | +577,220 | Add 155.86% | 947,570 | $58.07 |
| Q2 2024 | -601,531 | Reduce 61.89% | 370,350 | $45.70 |
| Q1 2024 | +890,651 | Add 1096.46% | 971,881 | $66.20 |
| Q4 2023 | -68,503 | Reduce 45.75% | 81,230 | $39.76 |
| Q3 2023 | -199,927 | Reduce 57.18% | 149,733 | $31.88 |
| Q2 2023 | +144,000 | Add 70.02% | 349,660 | $40.18 |
| Q1 2023 | -314,876 | Reduce 60.49% | 205,660 | $42.70 |
| Q4 2022 | +428,696 | Add 466.79% | 520,536 | $48.02 |
| Q3 2022 | +91,840 | New Buy | 91,840 | $37.62 |
| Q1 2022 | -63,028 | Sold Out | 0 | $0.00 |
| Q4 2021 | -85,572 | Reduce 57.59% | 63,028 | $58.51 |
| Q3 2021 | -254,007 | Reduce 63.09% | 148,600 | $39.56 |
| Q2 2021 | +179,445 | Add 80.41% | 402,607 | $42.47 |
| Q1 2021 | +9,362 | Add 4.38% | 223,162 | $61.55 |
| Q4 2020 | +133,000 | Add 164.60% | 213,800 | $70.54 |
| Q3 2020 | -71,500 | Reduce 46.95% | 80,800 | $38.56 |
| Q2 2020 | +152,300 | New Buy | 152,300 | $37.51 |
Steven Cohen's Keros Therapeutics Investment FAQs
Steven Cohen first purchased Keros Therapeutics, Inc. (KROS) in Q2 2020, acquiring 152,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Keros Therapeutics, Inc. (KROS) for 22 quarters since Q2 2020.
Steven Cohen's largest addition to Keros Therapeutics, Inc. (KROS) was in Q1 2024, adding 971,881 shares worth $64.34 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 109,015 shares of Keros Therapeutics, Inc. (KROS), valued at approximately $1.2 M.
As of the Q1 2026 filing, Keros Therapeutics, Inc. (KROS) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Keros Therapeutics, Inc. (KROS) was 971,881 shares, as reported at the end of Q1 2024.